Journal
Journal of nephrology
Publication Date
4-1-2022
Volume
35
Issue
3
First Page
875
Last Page
888
Document Type
Open Access Publication
DOI
10.1007/s40620-021-01241-5
Rights and Permissions
Coyne, D.W., Sprague, S.M., Vervloet, M. et al. Sucroferric oxyhydroxide for hyperphosphatemia: a review of real-world evidence. J Nephrol 35, 875–888 (2022). https://doi.org/10.1007/s40620-021-01241-5 This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Recommended Citation
Coyne, Daniel W; Sprague, Stuart M; Vervloet, Marc; Ramos, Rosa; and Kalantar-Zadeh, Kamyar, "Sucroferric oxyhydroxide for hyperphosphatemia: A review of real-world evidence." Journal of nephrology. 35, 3. 875 - 888. (2022).
https://digitalcommons.wustl.edu/oa_4/797
